Pharming Group Statistics

Total Valuation

Pharming Group has a market cap or net worth of EUR 1.00 billion. The enterprise value is 946.82 million.

Market Cap	1.00B
Enterprise Value	946.82M

Important Dates

The next confirmed earnings date is Thursday, May 7, 2026.

Earnings Date	May 7, 2026
Ex-Dividend Date	n/a

Share Statistics

Pharming Group has 706.25 million shares outstanding. The number of shares has increased by 11.25% in one year.

Current Share Class	706.25M
Shares Outstanding	706.25M
Shares Change (YoY)	+11.25%
Shares Change (QoQ)	+50.75%
Owned by Insiders (%)	1.55%
Owned by Institutions (%)	21.10%
Float	695.28M

Valuation Ratios

The trailing PE ratio is 412.14 and the forward PE ratio is 53.92.

PE Ratio	412.14
Forward PE	53.92
PS Ratio	3.12
PB Ratio	4.24
P/TBV Ratio	8.30
P/FCF Ratio	21.78
P/OCF Ratio	21.48
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 25.44, with an EV/FCF ratio of 20.60.

EV / Earnings	389.93
EV / Sales	2.96
EV / EBITDA	25.44
EV / EBIT	33.31
EV / FCF	20.60

Financial Position

The company has a current ratio of 2.59, with a Debt / Equity ratio of 0.42.

Current Ratio	2.59
Quick Ratio	1.97
Debt / Equity	0.42
Debt / EBITDA	2.69
Debt / FCF	2.15
Interest Coverage	3.06

Financial Efficiency

Return on equity (ROE) is 1.02% and return on invested capital (ROIC) is 2.92%.

Return on Equity (ROE)	1.02%
Return on Assets (ROA)	4.55%
Return on Invested Capital (ROIC)	2.92%
Return on Capital Employed (ROCE)	8.53%
Weighted Average Cost of Capital (WACC)	4.65%
Revenue Per Employee	787,109
Profits Per Employee	5,966
Employee Count	407
Asset Turnover	0.84
Inventory Turnover	0.75

Taxes

In the past 12 months, Pharming Group has paid 8.78 million in taxes.

Income Tax	8.78M
Effective Tax Rate	80.25%

Stock Price Statistics

The stock price has increased by +90.20% in the last 52 weeks. The beta is 0.12, so Pharming Group's price volatility has been lower than the market average.

Beta (5Y)	0.12
52-Week Price Change	+90.20%
50-Day Moving Average	1.41
200-Day Moving Average	1.32
Relative Strength Index (RSI)	45.73
Average Volume (20 Days)	11,311,398

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Pharming Group had revenue of EUR 320.35 million and earned 2.43 million in profits. Earnings per share was 0.00.

Revenue	320.35M
Gross Profit	281.60M
Operating Income	27.90M
Pretax Income	10.94M
Net Income	2.43M
EBITDA	33.74M
EBIT	27.90M
Earnings Per Share (EPS)	0.00

Full Income Statement

Balance Sheet

The company has 152.54 million in cash and 98.61 million in debt, giving a net cash position of 53.93 million or 0.08 per share.

Cash & Cash Equivalents	152.54M
Total Debt	98.61M
Net Cash	53.93M
Net Cash Per Share	0.08
Equity (Book Value)	236.01M
Book Value Per Share	0.34
Working Capital	156.44M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 46.59 million and capital expenditures -637,923, giving a free cash flow of 45.96 million.

Operating Cash Flow	46.59M
Capital Expenditures	-637,923
Depreciation & Amortization	5.86M
Net Borrowing	-3.62M
Free Cash Flow	45.96M
FCF Per Share	0.07

Full Cash Flow Statement

Margins

Gross margin is 87.90%, with operating and profit margins of 8.71% and 0.76%.

Gross Margin	87.90%
Operating Margin	8.71%
Pretax Margin	3.42%
Profit Margin	0.76%
EBITDA Margin	10.53%
EBIT Margin	8.71%
FCF Margin	14.35%

Dividends & Yields

Pharming Group does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.25%
Shareholder Yield	-11.25%
Earnings Yield	0.24%
FCF Yield	4.59%

Stock Splits

The last stock split was on March 5, 2013. It was a reverse split with a ratio of 0.1.

Last Split Date	Mar 5, 2013
Split Type	Reverse
Split Ratio	0.1

Scores

Pharming Group has an Altman Z-Score of 2.84 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.84
Piotroski F-Score	5